None
Quote | Gossamer Bio Inc. (NYSE:GOSS)
Last: | $ |
---|---|
Change Percent: | 1.20% |
Open: | $15.02 |
Close: | $15.21 |
High: | $15.22 |
Low: | $14.79 |
Volume: | 313,154 |
Last Trade Date Time: | 02/12/2020 04:40:17 pm |
News | Gossamer Bio Inc. (NYSE:GOSS)
2024-03-20 10:20:00 ET March 20, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech/Life Sciences sector. The newest biotech companies are involved in immuno-oncology, ...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced...
Message Board Posts | Gossamer Bio Inc. (NYSE:GOSS)
Subject | By | Source | When |
---|---|---|---|
Agreed! | Dutch4 | investorshub | 03/24/2023 5:03:33 PM |
Institutionals shorting this unmercilessly. Three trades totalling | hippityhop | investorshub | 12/22/2022 9:20:39 PM |
This is a 100/200 percenter in next 3 | hippityhop | investorshub | 12/19/2022 4:53:28 PM |
Raymond James Initiates Coverage On Gossamer Bio with | crudeoil24 | investorshub | 04/20/2022 11:43:11 PM |
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. | crudeoil24 | investorshub | 04/20/2022 11:41:45 PM |
News, Short Squeeze, Breakout and More Instantly...
2024-03-20 10:20:00 ET March 20, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech/Life Sciences sector. The newest biotech companies are involved in immuno-oncology, ...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced...
- First PAH Patient Dosed in Ongoing Registrational Phase 3 PROSERA Study - - Inclusion of Japan in Phase 3 PROSERA Study Following CTN Acceptance by PMDA - - Cash, cash equivalents and marketable securities totaled $296 million at year-end 2023 - Gossamer Bio, Inc. (Nas...